|
1
|
Src family kinases in tumor progression and metastasis.
|
Cancer Metastasis Rev
|
2003
|
4.62
|
|
2
|
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
|
Cancer Res
|
2009
|
4.19
|
|
3
|
Development and characterization of gemcitabine-resistant pancreatic tumor cells.
|
Ann Surg Oncol
|
2007
|
4.12
|
|
4
|
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
|
Cancer Res
|
2009
|
3.57
|
|
5
|
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice.
|
Nat Protoc
|
2009
|
3.36
|
|
6
|
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
|
Cancer Res
|
2008
|
2.59
|
|
7
|
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.
|
Oncogene
|
2005
|
2.53
|
|
8
|
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.
|
PLoS One
|
2011
|
2.49
|
|
9
|
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
|
Am J Pathol
|
2006
|
2.07
|
|
10
|
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.
|
Cancer
|
2002
|
2.03
|
|
11
|
Novel therapies for metastatic castrate-resistant prostate cancer.
|
J Natl Cancer Inst
|
2011
|
1.98
|
|
12
|
Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition.
|
Cell
|
2007
|
1.97
|
|
13
|
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
|
Clin Cancer Res
|
2012
|
1.92
|
|
14
|
Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells.
|
Clin Cancer Res
|
2002
|
1.88
|
|
15
|
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
|
J Natl Cancer Inst
|
2006
|
1.87
|
|
16
|
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.
|
Clin Cancer Res
|
2005
|
1.83
|
|
17
|
Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
|
Clin Cancer Res
|
2003
|
1.80
|
|
18
|
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers.
|
Gynecol Oncol
|
2003
|
1.75
|
|
19
|
Treatment for advanced tumors: SRC reclaims center stage.
|
Clin Cancer Res
|
2006
|
1.74
|
|
20
|
Src activation regulates anoikis in human colon tumor cell lines.
|
Oncogene
|
2002
|
1.70
|
|
21
|
The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression.
|
Breast Cancer Res Treat
|
2004
|
1.69
|
|
22
|
Src activation by β-adrenoreceptors is a key switch for tumour metastasis.
|
Nat Commun
|
2013
|
1.62
|
|
23
|
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer.
|
Lab Invest
|
2002
|
1.57
|
|
24
|
Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation.
|
Mol Cell Biol
|
2005
|
1.55
|
|
25
|
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation.
|
Cancer Res
|
2005
|
1.54
|
|
26
|
Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism.
|
J Biol Chem
|
2007
|
1.54
|
|
27
|
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
|
Cancer Res
|
2009
|
1.54
|
|
28
|
Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features.
|
Cancer
|
2008
|
1.50
|
|
29
|
Src continues aging: current and future clinical directions.
|
Clin Cancer Res
|
2007
|
1.50
|
|
30
|
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
|
Cancer
|
2011
|
1.49
|
|
31
|
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
|
Cancer Res
|
2003
|
1.41
|
|
32
|
Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells.
|
Mol Cancer Ther
|
2006
|
1.39
|
|
33
|
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
|
Cancer Res
|
2006
|
1.38
|
|
34
|
Steps in prostate cancer progression that lead to bone metastasis.
|
Int J Cancer
|
2011
|
1.34
|
|
35
|
Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis.
|
Cancer Res
|
2005
|
1.34
|
|
36
|
SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.
|
Anticancer Agents Med Chem
|
2007
|
1.32
|
|
37
|
Involvement of the conserved adaptor protein Alix in actin cytoskeleton assembly.
|
J Biol Chem
|
2006
|
1.30
|
|
38
|
AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts.
|
J Clin Invest
|
2007
|
1.30
|
|
39
|
Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells.
|
Clin Exp Metastasis
|
2006
|
1.26
|
|
40
|
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.
|
Expert Opin Investig Drugs
|
2011
|
1.24
|
|
41
|
BMP4 promotes prostate tumor growth in bone through osteogenesis.
|
Cancer Res
|
2011
|
1.23
|
|
42
|
Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy.
|
Ann Surg Oncol
|
2011
|
1.23
|
|
43
|
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example.
|
PLoS One
|
2009
|
1.20
|
|
44
|
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.
|
Cancer Discov
|
2013
|
1.18
|
|
45
|
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways.
|
Cancer Res
|
2003
|
1.17
|
|
46
|
AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells.
|
J Cell Physiol
|
2007
|
1.17
|
|
47
|
Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade.
|
Cancer Res
|
2007
|
1.14
|
|
48
|
c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK.
|
Pancreas
|
2005
|
1.14
|
|
49
|
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.
|
Mol Cancer Ther
|
2005
|
1.13
|
|
50
|
Pre-clinical mouse models of human prostate cancer and their utility in drug discovery.
|
Curr Protoc Pharmacol
|
2010
|
1.12
|
|
51
|
Gemcitabine resistance in pancreatic cancer: picking the key players.
|
Clin Cancer Res
|
2008
|
1.10
|
|
52
|
Src, chemoresistance and epithelial to mesenchymal transition: are they related?
|
Anticancer Drugs
|
2007
|
1.10
|
|
53
|
The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model.
|
Oncogene
|
2005
|
1.08
|
|
54
|
Functional roles of Src and Fgr in ovarian carcinoma.
|
Clin Cancer Res
|
2011
|
1.08
|
|
55
|
Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin.
|
Clin Exp Metastasis
|
2003
|
1.07
|
|
56
|
Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors.
|
Cancer Res
|
2005
|
1.06
|
|
57
|
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
|
Ann Surg
|
2005
|
1.06
|
|
58
|
Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells.
|
Angiogenesis
|
2006
|
1.03
|
|
59
|
Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors.
|
Expert Opin Ther Targets
|
2007
|
1.03
|
|
60
|
Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.
|
Mol Cancer Ther
|
2008
|
1.02
|
|
61
|
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis.
|
Mol Cancer Res
|
2013
|
1.01
|
|
62
|
Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells.
|
Mol Ther
|
2005
|
1.01
|
|
63
|
Decoding the intrinsic mechanism that prohibits ALIX interaction with ESCRT and viral proteins.
|
Biochem J
|
2010
|
0.98
|
|
64
|
A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis.
|
Am J Pathol
|
2003
|
0.97
|
|
65
|
SRC inhibitors as potential therapeutic agents for human cancers.
|
Mini Rev Med Chem
|
2006
|
0.96
|
|
66
|
Targeting SRC in mucinous ovarian carcinoma.
|
Clin Cancer Res
|
2011
|
0.93
|
|
67
|
Ligand-independent activation of MET through IGF-1/IGF-1R signaling.
|
Int J Cancer
|
2013
|
0.92
|
|
68
|
Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.
|
J Exp Ther Oncol
|
2007
|
0.91
|
|
69
|
Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.
|
Cancer Res
|
2003
|
0.91
|
|
70
|
Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
|
Int J Oncol
|
2007
|
0.88
|
|
71
|
Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
|
PLoS One
|
2012
|
0.88
|
|
72
|
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
|
Invest New Drugs
|
2012
|
0.87
|
|
73
|
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma.
|
Melanoma Res
|
2012
|
0.86
|
|
74
|
Extracellular Alix regulates integrin-mediated cell adhesions and extracellular matrix assembly.
|
EMBO J
|
2008
|
0.86
|
|
75
|
Src signaling pathways in prostate cancer.
|
Cancer Metastasis Rev
|
2014
|
0.86
|
|
76
|
Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression.
|
Cancer Res
|
2006
|
0.85
|
|
77
|
Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
|
Clin Cancer Res
|
2004
|
0.85
|
|
78
|
Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation.
|
Proc Natl Acad Sci U S A
|
2010
|
0.83
|
|
79
|
Targeting SRC and tubulin in mucinous ovarian carcinoma.
|
Clin Cancer Res
|
2013
|
0.83
|
|
80
|
Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
|
Int J Oncol
|
2006
|
0.81
|
|
81
|
AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
|
Neuro Oncol
|
2010
|
0.80
|
|
82
|
Src inhibitors in suppression of papillary thyroid carcinoma growth.
|
Head Neck
|
2013
|
0.80
|
|
83
|
Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells.
|
Mol Carcinog
|
2010
|
0.78
|
|
84
|
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.
|
Prostate
|
2013
|
0.78
|
|
85
|
Proteomics profiling of exosomes from primary mouse osteoblasts under proliferation versus mineralization conditions and characterization of their uptake into prostate cancer cells.
|
J Proteome Res
|
2017
|
0.75
|